The Boston, MA-based onclogy company develops
next-generation radiopharmaceuticals as precision medicines based on its
proprietary platform called Targeted Alpha Therapies (TAT) and its
proprietary Fast-Clear linker technology.
Lead candidate is FPI-1434,
a humanized monoclonal antibody targeting the insulin-like growth
factor 1 receptor (IGF-1R), a well-established tumor target, linked to
isotope actinium-225.
2019 Financials: Operating Expenses: $18.2M (+80%); Net Loss: ($16.2M) (-38%); Cash Burn: ($13.7M) (-38%).
https://seekingalpha.com/news/3580912-fusion-pharmaceuticals-readies-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.